Oppenheimer Initiates Coverage On Olema Pharmaceuticals with Outperform Rating, Announces Price Target of $21
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Matthew Biegler has initiated coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with an Outperform rating and a price target of $21.
July 21, 2023 | 8:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Olema Pharmaceuticals has been given an Outperform rating by Oppenheimer, with a price target of $21.
The Outperform rating from Oppenheimer indicates a positive outlook for Olema Pharmaceuticals. The price target of $21 suggests that the analyst believes the stock has potential for significant growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100